Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth
AbstractBackground: UV exposure-induced oxidative stress is implicated as a driving mechanism for melanoma. Increased oxidative stress results in DNA damage and epigenetic dysregulation. Accordingly, we explored whether a low dose of the antioxidant sulforaphane (SFN) in combination with the epigenetic drug 5-aza-2’-deoxycytidine (DAC) could slow melanoma cell growth. SFN is a natural bioactivated product of the cruciferous family, while DAC is a DNA methyltransferase inhibitor. Methods: Melanoma cell growth characteristics, gene transcription profiles, and histone epigenetic modifications were measured after single and combination treatments with SFN and DAC. Results: We detected melanoma cell growth inhibition and specific changes in gene expression profiles upon combinational treatments with SFN and DAC, while no significant alterations in histone epigenetic modifications were observed. Dysregulated gene transcription of a key immunoregulator cytokine—C-C motif ligand 5 (CCL-5)—was validated. Conclusions: These results indicate a potential combinatorial effect of a dietary antioxidant and an FDA-approved epigenetic drug in controlling melanoma cell growth. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 316 KB)
Share & Cite This Article
Chiang, T.-C.; Koss, B.; Su, L.J.; Washam, C.L.; Byrum, S.D.; Storey, A.; Tackett, A.J. Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth. Medicines 2019, 6, 71.
Chiang T-C, Koss B, Su LJ, Washam CL, Byrum SD, Storey A, Tackett AJ. Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth. Medicines. 2019; 6(3):71.Chicago/Turabian Style
Chiang, Tung-chin; Koss, Brian; Su, L. J.; Washam, Charity L.; Byrum, Stephanie D.; Storey, Aaron; Tackett, Alan J. 2019. "Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth." Medicines 6, no. 3: 71.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.